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mia and thus the potential for spontaneous sustained tachy- 
arrhythmia. Such reasoning is based on an implicit assump- 
tion that the conditions prevailing during the electrophysio- 
logic study will not change significantly during the 
subsequent follow-up period. 
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In patients with recurrent malignant ventricular arrhythmias, 
electrophysiologic testing has been shown to be useful in 
identifying effective antiarrhythmic regimens (l-4). Patients 
in whom a sustained ventricular tachyarrhythmia can be 
initiated by programmed stimulation during a baseline study 
and whose arrhythmia is no longer inducible during antiar- 
rhythmic therapy have a significantly lower recurrence rate 
of the spontaneous arrhythmia than that of patients receiving 
long-term treatment with a regimen that failed to prevent 
initiation of the arrhythmia during electrophysiologic testing. 
However, the recurrence rate of malignant ventricular ar- 
rhythmia in patients treated with an “effective” regimen, as 
determined during electrophysiologic testing, is not inconse- 
quential. It ranges from 5% to 32% within the 2 years after 
electrophysiologic evaluation (l-6). Particularly when the 
arrhythmia is poorly tolerated, such recurrences are of great 
clinical significance. 
Electrophysiologic study for evaluation of antiarrhythmic 
efficacy in malignant ventricular arrhythmias is based on the 
hypothesis that the substrate for these reentrant arrhythmias 
is fixed and present at all times. Thus, the electrophysiologic 
stress of programmed stimulation will create the appropriate 
conditions for initiation and perpetuation of the arrhythmia. 
An alteration in the fixed arrhythmogenic milieu or a change 
in the interaction between the stress (programmed stimula- 
tion) and the arrhythmogenic substrate caused by the anti- 
arrhythmic regimen will alter the inducibility of the arrhyth- 
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previously identified as effective during electrophysiologic 
studies. There are several potential explanations for such 
failure. These include poor patient compliance, progression 
of the underlying disease, and therefore alterations in the 
arrhythmogcnic substrate. and spontaneous variability dur- 
ing electrophysiologic testing. 
Certainly. poor patient compliance with antiarrhythmic 
regimens can explain the failure of apparently effective 
regimens to control malignant ventricular arrhythmias. Most 
investigators and clinicians believe that compliance with 
medical regimens is high in this group of patients with 
life-threatening arrhythmias. However, few objective data 
are available that correlate plasma drug concentrations at the 
time of arrhythmia recurrence with drug concentrations 
previously found effective during electrophysiologic testing. 
Progression of the underlying disease and alterations in 
the arrhythmogenic srrbsrrate are possible, although limited 
data are available to evaluate this possibility. When electro- 
physiologic studies have been repeated in patients after 
intervals of months to years. the results of programmed 
stimulation are similar or identical in most patients (7,s). 
Progression of disease probably does not explain many 
arrhythmia recurrences in patients receiving treatment that 
was predicted to be effective. 
Spontaneous variabiliry in the inducibility qf sustained 
ventricular tachyarrhythmias during programmed stimula- 
tion is a possible explanation for spontaneous recurrences of 
arrhythmia in patients treated with regimens that prevented 
induction of the arrhythmia during testing. In this scenario, 
the failure to induce the arrhythmia during the drug evalua- 
tion study would be caused by a lack of reproducibility of 
arrhythmia induction rather than drug effect. Several studies 
(9-1 I) have evaluated the reproducibility of programmed 
stimulation in patients with malignant ventricular arrhyth- 
mias. Whereas some variability is present, when reproduc- 
ibility is defined as induction of a sustained ventricular 
tachyarrhythmia with use of a complete stimulation protocol 
that includes three ventricular extrastimuli, the arrhythmia is 
reproducibly initiated on the same day or on subsequent 
days in 80% to 90% of patients (9-11). Spontaneous variabil- 
ity is a reality and probably contributes to the recurrence of 
arrhythmia in some patients on apparently effective regi- 
mens. It does not, however, appear to explain it completely. 
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Alteration of sympathetic tone during electrophysiologic 
testing. A potentially important and heretofore largely un- 
studied explanation for recurrent ventricular arrhythmia is 
that the electrophysiologic conditions prevailing at the time 
of the electrophysiologic study may not represent the con- 
ditions that prevail during the follow-up period. The study by 
Jazayeri and coworkers (12) in this issue of the Journal is a 
significant addition to our understanding of this phcnome- 
non. They assessed the effect of increased sympathetic 
stimulation in patients in whom previously inducible ventric- 
ular tachycardia was no longer inducible during antiarrhyth- 
mic therapy. In more than half of their patients, isoprotere- 
no1 reversed the protective effect of the previously effective 
antiarrhythmic regimen and ventricular tachyarrhythmia 
was once again inducible during the isoproterenol infusion. 
Recurrent arrhythmia was not observed during the follow-up 
period in patients in whom isoproterenol infusion did not 
reverse the suppressive effects of the antiarrhythmic regi- 
men. Conversely, during the 1st year of follow-up, recurrent 
arrhythmia was observed in 30% of patients in whom iso- 
proterenol had restored inducibility of the arrhythmia. Each 
episode of recurrent arrhythmia occurred during an activity 
that would be expected to increase sympathetic tone. In two 
of these patients who were subsequently treated with a 
beta-adrenergic blocking agent, recurrent arrhythmia was 
not documented. This finding further supports the suggestion 
that sympathetic stimulation was responsible for the reversal 
of the antiarrhythmic efficacy. Other investigators, most 
notably Fisher and coworkers (13). have suggested adding 
beta-blockers to the classic antiarrhythmic regimen in such 
patients. 
What is thr clinical implication of this observation? 
Concurrent therapy with a beta-adrenergic blocking agent 
seems appropriate when possible. Other suggestions remain 
speculative. Should an apparently effective regimen whose 
suppressive etfect is reversed by isoproterenol be abandoned 
and subsequent drug testing with different regimens be 
pursued’? Should therapy with an antitachycardia device or 
an implantable defibrillator be selected instead of antiar- 
rhythmic drug therapy? The answers are not known. Before 
this technique is adopted as routine. confirmatory studies in 
a larger number of patients with longer follow-up are neces- 
sary. In such studies, the aforementioned questions can be 
prospectively addressed. 
Additional perturbations in the electrophysiologic milieu 
during electrophysiologic testing. The study by Jazayeri and 
coworkers (12) raises the question of which other variables 
can and should be manipulated during electrophysiologic 
testing to more accurately mimic those conditions that may 
prevail during follow-up..Additional extrastimuli. above thk 
number required to initiate the arrhythmia during baseline 
studies. are an obvious choice. The extrastimuli alter the 
electrophysiologic conditions in the reentrant circuit and 
surrounding ventricular myocardium. The addition of one 
extrastimulus appears to significantly reduce the spontane- 
ous variability of arrhythmia induction and additional extra- 
stimuli may further simulate conditions outside the labora- 
tory. Some data are available and support the utility of 
additional extrastimuli in selecting antiarrhythmic regimens 
(14.15). 
Would other changes in the electrophysio[ogic milieu he 
helplful in simulating the clinical vuriahility of rhe arrhyth- 
mogenic substrate and would they be safe? One can envision 
the induction of ischemia with supine exercise or infusion of 
dipyridamole or adenosine. Short-term alterations in plasma 
electrolyte concentrations or in ventricular loading condi- 
tions might also be very likely to alter the inducibility of 
ventricular arrhythmias. Psychological stress, which has 
been implicated in the spontaneous occurrence of malignant 
arrhythmia, can also be assessed by a variety of techniques 
during electrophysiologic testing. 
Mosr importantly, thr sajcty of such interventions must 
he assessed. How much time these procedures will consume 
and whether they are feasible during electrophysiologic 
testing are not certain. If used, how these perturbations will 
affect the sensitivity, specificity, predictive value and repro- 
ducibility of electrophysiologic testing must be determined 
in a large number of patients followed up for several years. 
Even if such perturbations produce clinically useful in- 
formation, will patients (and their electrophysiologists) be 
able to tolerate such extensive studies? Improvements in the 
electrophysiologic evaluation of antiarrhythmic regimens in 
patients with malignant ventricular arrhythmias is certainly 
possible. One question we must answer, however, is how 
much stress (electrophysiologic or other) is enough? 
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